

Image

1645

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on November 12, 2003.

INFORMATION DISCLOSURE STATEMENT
Examining Group 1645
Patent Application
Docket No. G-101US05REG
Serial No. 10/051,681

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Unknown
Art Unit : 1645
Applicant(s) : Daniel Cohen and Ilya Chumakov
Serial No. : 10/051,681
Filed : January 16, 2002
Conf. No. : 1458
For : Treatment of CNS Disorders Using D-Amino Acid Oxidase and D-Aspartate Oxidase Antagonists

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:


In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate

marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted,



Frank C. Eisenschenk
Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: Saliwanchik, Lloyd & Saliwanchik
A Professional Association
2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

FCE/sssa

Attachments: Form PTO/SB/08B (1 page)
Copies of references cited (4)



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known			
		Application Number	10/211,160		
		Filing Date	August 1, 2002		
		First Named Inventor	Daniel Cohen		
		Group Art Unit	1615		
		Examiner Name	Unassigned		
Sheet	1	of	1	Attorney Docket Number	G-101US06CIP

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	GREENE, R. "Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia", <i>Hippocampus</i> , 2001, 11(5):569-577.	
	R2	FUKUI, K. and Y. Miyake. "Molecular cloning and chromosomal localization of a human gene encoding D-amino-acid oxidase" <i>J. Biol. Chem.</i> , 1992, 267(26):18631-18638.	
	R3	MOTHET, J-P. et al. "D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor", <i>PNAS</i> , 2000, 97(9):4926-4931.	
	R4	HERESCO-LEVY, U. "N-methyl-D-aspartate (NMDA) receptor-based treatment approaches in schizophrenia: the first decade", <i>Intl. J. Neuropsychopharmacol</i> , 2000, 3:243-258.	
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.